USANA Health Sciences (NYSE:USNA) Stock Price Expected to Rise, DA Davidson Analyst Says

USANA Health Sciences (NYSE:USNA) had its price objective upped by DA Davidson from $35.00 to $38.00 in a research report report published on Thursday morning,Benzinga reports. DA Davidson currently has a neutral rating on the stock.

Separately, StockNews.com upgraded shares of USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 28th.

USANA Health Sciences Price Performance

USNA stock opened at $36.17 on Thursday. USANA Health Sciences has a 1 year low of $31.44 and a 1 year high of $52.75. The firm has a market capitalization of $689.40 million, a PE ratio of 12.78, a price-to-earnings-growth ratio of 1.25 and a beta of 0.89. The business has a 50 day simple moving average of $37.86 and a 200-day simple moving average of $39.55.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.07. The business had revenue of $200.22 million during the quarter, compared to the consensus estimate of $208.45 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. During the same period last year, the company earned $0.59 EPS. On average, equities research analysts expect that USANA Health Sciences will post 2.45 EPS for the current year.

Insider Transactions at USANA Health Sciences

In other USANA Health Sciences news, Director Gilbert A. Fuller sold 675 shares of the stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $37.71, for a total transaction of $25,454.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.33% of the company’s stock.

Institutional Investors Weigh In On USANA Health Sciences

Several large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its stake in shares of USANA Health Sciences by 5.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 97,375 shares of the company’s stock worth $4,405,000 after purchasing an additional 5,205 shares during the period. Rhumbline Advisers boosted its position in shares of USANA Health Sciences by 7.1% in the 2nd quarter. Rhumbline Advisers now owns 36,486 shares of the company’s stock worth $1,651,000 after buying an additional 2,425 shares in the last quarter. TD Asset Management Inc raised its position in USANA Health Sciences by 26.4% during the second quarter. TD Asset Management Inc now owns 11,500 shares of the company’s stock worth $520,000 after acquiring an additional 2,400 shares during the last quarter. American Century Companies Inc. lifted its stake in USANA Health Sciences by 12.3% in the 2nd quarter. American Century Companies Inc. now owns 159,782 shares of the company’s stock valued at $7,229,000 after buying an additional 17,460 shares in the last quarter. Finally, BOKF NA raised its holdings in shares of USANA Health Sciences by 99.4% in the second quarter. BOKF NA now owns 5,526 shares of the company’s stock worth $250,000 after acquiring an additional 2,755 shares during the last quarter. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.